Cargando…

Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms

BACKGROUND: The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-month treatment period with risperidone long-acting injection (RLAI), adjunctive to an individual's treatment regimen, in subjects with symptomatic bipolar disorder who relapsed freque...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macfadden, Wayne, Adler, Caleb M, Turkoz, Ibrahim, Haskins, John T, Turner, Norris, Alphs, Larry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219580/ https://www.ncbi.nlm.nih.gov/pubmed/22034906 http://dx.doi.org/10.1186/1471-244X-11-171

Ejemplares similares

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
por: Markowitz, Michael, et al.
Publicado: (2013)

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)
por: Crivera, Concetta, et al.
Publicado: (2011)

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011)

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results
por: Macfadden, Wayne, et al.
Publicado: (2011)

Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection
por: El-Hage, Wissam, et al.
Publicado: (2010)

Risperidone in the treatment of bipolar mania
por: Sajatovic, Martha, et al.
Publicado: (2006)

Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
por: Ranjbar, Fatemeh, et al.
Publicado: (2015)

Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection
por: Samalin, L, et al.
Publicado: (2010)

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium
por: Lambert, Tim, et al.
Publicado: (2011)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao, Yueren, et al.
Publicado: (2013)

Bipolar Disorder with frequent mood episodes in the National Comorbidity Survey Replication (NCS-R)
por: Nierenberg, Andrew A., et al.
Publicado: (2009)

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
por: Alphs, Larry, et al.
Publicado: (2011)

Risperidone treatment for ADHD in children and adolescents with bipolar disorder
por: Biederman, Joseph, et al.
Publicado: (2008)

Risperidone Mono - Therapy as Prophylaxis in Bipolar Affective Disorders
por: Trivedi, Mohit, et al.
Publicado: (2004)

Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments
por: Frye, Mark A, et al.
Publicado: (2015)

Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial
por: Yatham, L N, et al.
Publicado: (2016)

Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature
por: Fabrazzo, Michele, et al.
Publicado: (2021)

Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia
por: Bishop, Jeffrey R, et al.
Publicado: (2008)

Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania
por: Rezayat, Amir Akhavan, et al.
Publicado: (2014)

Topiramate versus Valproate Sodium as Adjunctive Therapies to a Combination of Lithium and Risperidone for Adolescents with Bipolar I Disorder: Effects on Weight and Serum Lipid Profiles
por: Mahmoudi-Gharaei, Javad, et al.
Publicado: (2012)

Risperidone Versus Risperidone Plus Sodium Valproate for Treatment of Bipolar Disorders: A Randomized, Double-Blind Clinical-Trial
por: Moosavi, S. Mohammad, et al.
Publicado: (2014)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Report of three cases that received maintenance treatment with risperidone as a mood stabilizer
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2004)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
por: Schreiner, A, et al.
Publicado: (2015)

Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
por: Nakamura, Yusuke, et al.
Publicado: (2019)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Gabriel, Adel
Publicado: (2010)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial
por: Raghuthaman, G., et al.
Publicado: (2015)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
por: Hori, Hikaru, et al.
Publicado: (2018)

Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder
por: Bossie, Cynthia A., et al.
Publicado: (2017)

Mood dynamics in bipolar disorder
por: Moore, Paul J, et al.
Publicado: (2014)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

Oral mucositis induced by risperidone: rare side effect of a frequently prescribed medication
por: Aguglia, Andrea, et al.
Publicado: (2020)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa, Jennifer Kern, et al.
Publicado: (2012)

Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate
por: Sliwa, Jennifer Kern, et al.
Publicado: (2014)

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016)

Providing Incentives on a Smartphone-Based Mood Relapse Warning Application among Patients with Bipolar Disorder
por: Lin, Y.-H., et al.
Publicado: (2023)

Effect Of Risperidone And Olanzapine On The Metabolic Profile Of Drug Naïve Bipolar Disorder Patients.
por: Gupta, Gajal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r6r85dmnj7pl67bg858fdo4802